• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death.

作者信息

Song Kyung-A, Faber Anthony C

机构信息

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, VA, USA.

出版信息

J Thorac Dis. 2019 Jun;11(6):E82-E85. doi: 10.21037/jtd.2019.06.11.

DOI:10.21037/jtd.2019.06.11
PMID:31372302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6626797/
Abstract
摘要

相似文献

1
Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death.上皮-间质转化与耐药性：摆脱死亡的转变
J Thorac Dis. 2019 Jun;11(6):E82-E85. doi: 10.21037/jtd.2019.06.11.
2
Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.前列腺癌治疗反应中上皮-间质转化控制下的细胞死亡
Int J Urol. 2018 Apr;25(4):318-326. doi: 10.1111/iju.13505. Epub 2018 Jan 17.
3
Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.硝唑尼特抑制拉帕替尼耐药的人表皮生长因子受体2阳性乳腺癌中的上皮-间质转化和肿瘤生长。
Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.
4
Epithelial-mesenchymal plasticity-engaging stemness in an interplay of phenotypes.上皮-间质可塑性在表型相互作用中赋予干性。
Stem Cell Investig. 2019 Aug 20;6:25. doi: 10.21037/sci.2019.08.08. eCollection 2019.
5
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis.混合上皮/间充质表型在转移中的意义。
Front Oncol. 2015 Jul 20;5:155. doi: 10.3389/fonc.2015.00155. eCollection 2015.
6
Roles of epithelial-mesenchymal transition in cancer drug resistance.上皮-间充质转化在癌症药物耐药中的作用。
Curr Cancer Drug Targets. 2013 Nov;13(9):915-29. doi: 10.2174/15680096113136660097.
7
Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma.猫口腔鳞状细胞癌中上皮-间充质转化的免疫组织化学特征。
Vet Pathol. 2019 Nov;56(6):826-839. doi: 10.1177/0300985819859873. Epub 2019 Jul 22.
8
Src, chemoresistance and epithelial to mesenchymal transition: are they related?Src、化学抗性与上皮-间质转化：它们有关联吗？
Anticancer Drugs. 2007 Apr;18(4):371-5. doi: 10.1097/CAD.0b013e32801265d7.
9
Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.上皮-间质转化：癌症转移与耐药性之间的联系
Crit Rev Oncog. 2017;22(3-4):275-282. doi: 10.1615/CritRevOncog.2018024855.
10
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.靶向上皮-间质转化（EMT）以克服癌症中的耐药性
Molecules. 2016 Jul 22;21(7):965. doi: 10.3390/molecules21070965.

引用本文的文献

1
Resistance Signatures Manifested in Early Drug Response in Cancer and Across Species.癌症及跨物种早期药物反应中表现出的耐药特征
bioRxiv. 2025 May 18:2024.07.05.602281. doi: 10.1101/2024.07.05.602281.
2
Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy.传统抗癌疗法的进展与局限：手术、化疗、放疗及激素疗法的全面综述
Discov Oncol. 2025 Apr 24;16(1):607. doi: 10.1007/s12672-025-02198-8.
3
A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in -mutated -amplified non-small cell lung cancer.一种新型间充质上皮转化（MET）抑制剂CB538可缓解EGFR突变、EGFR扩增的非小细胞肺癌中的获得性耐药。
Transl Cancer Res. 2025 Mar 30;14(3):1915-1927. doi: 10.21037/tcr-24-1614. Epub 2025 Mar 24.
4
NINJ1 in Cell Death and Ferroptosis: Implications for Tumor Invasion and Metastasis.NINJ1在细胞死亡和铁死亡中的作用：对肿瘤侵袭和转移的影响
Cancers (Basel). 2025 Feb 26;17(5):800. doi: 10.3390/cancers17050800.
5
Phenotypic Plasticity and Cancer: A System Biology Perspective.表型可塑性与癌症：系统生物学视角
J Clin Med. 2024 Jul 23;13(15):4302. doi: 10.3390/jcm13154302.
6
Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds.共存的单克隆细胞亚群中的信号动力学揭示了对抗癌化合物耐药的机制。
Cell Commun Signal. 2024 Jul 26;22(1):377. doi: 10.1186/s12964-024-01742-3.
7
Diverse temporal and spatial mechanisms work, partially through Stanniocalcin-1, V-ATPase and senescence, to activate the extracellular ATP-mediated drug resistance in human cancer cells.多种时空机制发挥作用，部分通过1型鲟鱼钙蛋白、V型质子ATP酶和细胞衰老，激活人类癌细胞中细胞外ATP介导的耐药性。
Front Oncol. 2024 Feb 6;14:1276092. doi: 10.3389/fonc.2024.1276092. eCollection 2024.
8
Targeting HER3 to overcome EGFR TKI resistance in NSCLC.针对 HER3 克服 NSCLC 中 EGFR TKI 耐药性。
Front Immunol. 2024 Jan 4;14:1332057. doi: 10.3389/fimmu.2023.1332057. eCollection 2023.
9
Study of the antioxidant and anti-pancreatic cancer activities of aqueous extracts obtained by maceration and ultrasonic extraction techniques.浸渍法和超声提取法所得水提取物的抗氧化及抗胰腺癌活性研究
Front Pharmacol. 2023 Aug 1;14:1201969. doi: 10.3389/fphar.2023.1201969. eCollection 2023.
10
Is cancer an intelligent species?癌症是一种智能物种吗？
Cancer Metastasis Rev. 2023 Dec;42(4):1201-1218. doi: 10.1007/s10555-023-10123-0. Epub 2023 Aug 4.

本文引用的文献

1
How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.细胞凋亡和上皮-间质转化如何与肺癌中表皮生长因子受体（EGFR）抑制剂耐药相关。
J Thorac Dis. 2019 Jan;11(1):47-49. doi: 10.21037/jtd.2018.12.117.
2
From "high" ZEB1 to "low" B-cell lymphoma 2-interacting mediator of cell death (BIM)-an epithelial-mesenchymal transition (EMT)-associated drug resistance pathway elucidated.从“高”ZEB1到“低”细胞死亡的B细胞淋巴瘤2相互作用介质（BIM）——一种上皮-间质转化（EMT）相关的耐药途径得以阐明。
J Thorac Dis. 2019 Jan;11(1):1-5. doi: 10.21037/jtd.2018.12.70.
3
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.靶向 EMT 转录因子 TWIST1 克服 EGFR 突变型非小细胞肺癌对 EGFR 抑制剂的耐药性。
Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.
4
OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.OVOL2 通过精细调控鼻咽癌中的上皮-间充质转化来连接干性和转移。
Theranostics. 2018 Mar 8;8(8):2202-2216. doi: 10.7150/thno.24003. eCollection 2018.
5
Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.miR-483-3p 的表观遗传沉默通过靶向整合素 β3 促进 EGFR 突变型 NSCLC 获得性吉非替尼耐药和 EMT。
Oncogene. 2018 Aug;37(31):4300-4312. doi: 10.1038/s41388-018-0276-2. Epub 2018 May 2.
6
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.上皮-间充质转化通过抑制 BIM 拮抗肺癌对靶向治疗的反应。
Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19.
7
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.针对具有 EMT 特征的获得性 EGFR-TKI 耐药非小细胞肺癌细胞中的 miR-200c/LIN28B 轴。
Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.
8
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.上皮-间质转化定义了KRAS突变型肺癌中MEK抑制诱导的受体酪氨酸激酶信号的反馈激活。
Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6.
9
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.在多种急性淋巴细胞白血病转基因小鼠模型中，BIM介导癌基因失活诱导的细胞凋亡。
Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731.
10
Progression and metastasis of lung cancer.肺癌的进展与转移
Cancer Metastasis Rev. 2016 Mar;35(1):75-91. doi: 10.1007/s10555-016-9618-0.